Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
22
pubmed:dateCreated
2010-11-26
pubmed:abstractText
Effectiveness of double umbilical cord blood (dUCB) grafts relative to conventional marrow and mobilized peripheral blood from related and unrelated donors has yet to be established. We studied 536 patients at the Fred Hutchinson Cancer Research Center and University of Minnesota with malignant disease who underwent transplantation with an human leukocyte antigen (HLA)-matched related donor (MRD, n = 204), HLA allele-matched unrelated donor (MUD, n = 152) or 1-antigen-mismatched unrelated adult donor (MMUD, n = 52) or 4-6/6 HLA matched dUCB (n = 128) graft after myeloablative conditioning. Leukemia-free survival at 5 years was similar for each donor type (dUCB 51% [95% confidence interval (CI), 41%-59%]; MRD 33% [95% CI, 26%-41%]; MUD 48% [40%-56%]; MMUD 38% [95% CI, 25%-51%]). The risk of relapse was lower in recipients of dUCB (15%, 95% CI, 9%-22%) compared with MRD (43%, 95% CI, 35%-52%), MUD (37%, 95% CI, 29%-46%) and MMUD (35%, 95% CI, 21%-48%), yet nonrelapse mortality was higher for dUCB (34%, 95% CI, 25%-42%), MRD (24% (95% CI, 17%-39%), and MUD (14%, 95% CI, 9%-20%). We conclude that leukemia-free survival after dUCB transplantation is comparable with that observed after MRD and MUD transplantation. For patients without an available HLA matched donor, the use of 2 partially HLA-matched UCB units is a suitable alternative.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1528-0020
pubmed:author
pubmed:issnType
Electronic
pubmed:day
25
pubmed:volume
116
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
4693-9
pubmed:meshHeading
pubmed-meshheading:20686119-Adolescent, pubmed-meshheading:20686119-Adult, pubmed-meshheading:20686119-Aged, pubmed-meshheading:20686119-Child, pubmed-meshheading:20686119-Cord Blood Stem Cell Transplantation, pubmed-meshheading:20686119-Disease-Free Survival, pubmed-meshheading:20686119-Female, pubmed-meshheading:20686119-Graft vs Host Disease, pubmed-meshheading:20686119-HLA Antigens, pubmed-meshheading:20686119-Hematologic Neoplasms, pubmed-meshheading:20686119-Hematopoiesis, pubmed-meshheading:20686119-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:20686119-Humans, pubmed-meshheading:20686119-Leukemia, pubmed-meshheading:20686119-Male, pubmed-meshheading:20686119-Middle Aged, pubmed-meshheading:20686119-Recurrence, pubmed-meshheading:20686119-Transplantation, Homologous, pubmed-meshheading:20686119-Umbilical Cord, pubmed-meshheading:20686119-Young Adult
pubmed:year
2010
pubmed:articleTitle
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood.
pubmed:affiliation
University of Minnesota Medical Center, Minneapolis, MN, USA. runs072@umn.edu
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural